InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Lime Time Free
04/12/24 8:37 PM
profile icon
Renee PremiumMember
04/12/24 6:15 PM
profile icon
Zchef Free
03/27/24 9:11 AM
profile icon
I-Glow PremiumMember
03/25/24 4:08 PM
profile icon
I-Glow PremiumMember
03/25/24 3:44 PM
profile icon
double_m Free
03/13/24 4:41 PM
profile icon
double_m Free
02/23/24 4:29 PM
profile icon
Here Today PremiumMember
02/22/24 4:44 PM
profile icon
double_m Free
02/22/24 4:06 PM
profile icon
1776club Free
02/20/24 5:10 PM
profile icon
1776club Free
02/20/24 4:59 PM
profile icon
G-lupo Free
01/22/24 1:52 PM
Bullish
Bullish
profile icon
Here Today PremiumMember
01/18/24 8:47 PM
profile icon
Here Today PremiumMember
01/18/24 3:26 PM
profile icon
Here Today PremiumMember
01/08/24 4:01 PM
profile icon
Here Today PremiumMember
01/08/24 3:56 PM
profile icon
Harbor6460 Free
01/06/24 12:08 PM
profile icon
Au$tin Free
12/26/23 2:54 PM
profile icon
XWAVXALMIMAN Free
12/24/23 11:08 PM
Bullish
Bullish
profile icon
Au$tin Free
12/24/23 7:36 PM
profile icon
retireat40 Free
12/22/23 3:57 PM
profile icon
retireat40 Free
12/22/23 2:06 PM
profile icon
Here Today PremiumMember
12/22/23 11:54 AM
profile icon
Here Today PremiumMember
12/22/23 11:53 AM
profile icon
G-lupo Free
12/22/23 11:46 AM
profile icon
Here Today PremiumMember
12/22/23 11:43 AM
profile icon
G-lupo Free
12/22/23 11:39 AM
profile icon
G-lupo Free
12/22/23 9:52 AM
profile icon
XWAVXALMIMAN Free
12/22/23 4:08 AM
Bullish
Bullish
profile icon
KellySueNews Free
12/21/23 1:23 PM
profile icon
KellySueNews Free
12/21/23 12:12 PM
profile icon
traveller Free
12/21/23 11:07 AM
profile icon
James salmon Free
12/21/23 11:07 AM

Sorrento Therapeutics Inc (SRNE) RSS Feed

Followers
285
Posters
706
Posts (Today)
0
Posts (Total)
14939
Created
03/09/07
Type
Free
Moderators Brandywhitneylady

Sorrento Stock Has Multiple Catalysts in Play; Analyst Says ‘Buy’

Some companies favor a "do one job and do it well" approach. However, that is not the Sorrento Therapeutics (SRNE) way.

While being laser-focused on just one objective can have its advantages, having a wider-based remit can be just as effective, if done well.

That is certainly the opinion of Alliance Global analyst James Molloy when evaluating Sorrento’s prospects.

“SRNE combines one of the most active and promising pipelines in the COVID space with a potentially transformative non-opioid pain pipeline, and adds in a deep oncology pipeline,” the analyst said. “Most of SRNE's pipeline has significant catalysts over the next 1-4 quarters, with multiple late-stage clinical data read-outs and multiple potential Emergency Use Authorization (EUA) launches as well.”

So, what’s on offer from the Sorrento menu in the near-term?

The company has already filed an EUA for COVI-STIX, a 15-minute nasal swab antigen test for SARS-CoV-2, in the US and Mexico, and the test could be launched as early as 1H21.

Accurate COVID tests are still needed in the US and around the globe, and Molloy expects the assay to gain EUA approval and could “rapidly approach $500M in sales as soon as 2022.“

SRNE's 8-minute SARS-CoV-2 antibody test COVID-TRACK could swiftly follow in its footsteps with an EUA anticipated to be filed in the year’s first half, too. “This could easily be another $500million+ near term opportunity,” Molloy said.

Furthermore, the company’s two neutralizing antibody treatments, COVI-DROPS and COVI-AMG, against SARS-CoV-2, could be launched in 2022. Each of these, as well, have the potential to bring in more than $500 million in sales, according to the analyst

The company’s non-opioid pain pipeline also has several late-stage catalysts.

Fast tracked by the FDA, Phase 3 data for sciatica pain candidate SP-102 should be available this year, while RTX for OsteoArthritis (OA) knee pain and intractable cancer pain will kick-off Phase 2 and Phase 3 studies, respectively, in 2021. Both target “substantial market opportunities.”

Last but not least is Abivertinib, the company's oncology lead candidate, indicated for non-small-cell lung cancer (NSCLC) and B-cell lymphomas, and currently in Phase 3 trials in China with top line data anticipated in 1H21.

To this end, based on the progress of the company's pipeline, Molloy sees significant gains in SRNE's future. The analyst rates the stock a Buy and his $35 price target implies a hefty 277% upside. (To watch Molloy’s track record, click here)

Overall, Sorrento currently has few, yet very positive analysts tracking its progress. With Buy ratings only – 3, in total - the stock has a Strong Buy consensus rating. There’s plenty of upside projected, too; At $28.67, the average price target suggests gains of ~209% over the next 12 months. (See SRNE stock analysis on TipRanks)

Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Originally published January 25,2021

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products.
It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars,
immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.
The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.
 

SORRENTO THERAPEUTICS, INC.

4955 Directors Place

San Diego, CA 92121

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™, Gene-MAb™, COVI-MSC™ and COVI-DROPS™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™. 

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018. 

For more information visit?